Government Response

The Government responded to this petition on Wednesday 12th October 2016

Stem cell transplantation is available for patients with Waldenstrom’s macroglobulinaemia and continues to be funded by NHS England where it is the most appropriate clinical option.

Waldenstrom’s macroglobulinaemia (WM) is a rare form of blood cancer. The condition is characterised by a slow progression and patients are managed on a case by case basis as symptoms develop. In a small proportion of cases a stem cell transplant is the most appropriate form of treatment.

NHS England published the criteria used for routine clinical commissioning of stem cell transplants in 2013 which is available at: www.england.nhs.uk/wp-content/uploads/2013/04/b04-p-a.pdf. This commissioning policy for stem transplants reflects the professional consensus on the benefit and risk of a transplant for different conditions that was available when the policy was formulated. In the UK this guidance came from the British Society for Blood and Bone Marrow Transplantation (BSBMT) in the form of best-practice guides for treatment of adults (2012) and children (2011). This guidance is regularly updated to take account of developments in clinical practice. WM was only added to the guidance in September 2013 and therefore NHS England did not include this condition as part of the overall clinical commissioning policy. This means that NHS England does not routinely commission stem cell treatments for WM patients and that funding of stem cell transplants for these patients has involved other funding mechanisms. Over the last few years some patients have received a stem cell transplant to treat WM. In these cases funding may have involved an Individual Funding Request (IFRs) or been directly funded from an NHS trust.

Each year, NHS England receives proposals for new drugs, medical devices or interventions for use by specialised services in England. NHS England has to make difficult operational decisions on behalf of tax-payers about how to prioritise the funding that is available for new investments. NHS England needs to ensure it focuses resources on those interventions which deliver the best results for patients, taking into account the evidence for clinical benefit and cost.

Proposals are reviewed by the Clinical Priorities Advisory Group (CPAG) that follows a published procedure. A proposal to routinely commission transplant for patients with WM will be considered by CPAG later this year and NHS Trusts will be informed of the outcome. Until that time, clinicians can continue to apply for funding for stem cell transplant for patient with WM where it can be demonstrated that a transplant is the most appropriate treatment option.

Department of Health